Compare GSK plc (GSK) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? GSK plc trades at $46.77 (market cap $91.88B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.51 (market cap $2.27B). The key difference: GSK plc is far larger — about 40.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and GSK plc pays a 3.9% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| GSK | SLS | |
|---|---|---|
Market Cap | $91.88B | $2.27B |
Volume | 7,730,529 | 4,179,659 |
Sector | Health | Health |
52-Week High | $61.18 | $15.46 |
52-Week Low | $43.24 | $1.39 |
Typical Hold Time | 93 Days | — |
Enterprise Value | $111.88B | $2.14B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
